The latest price target for Boundless Bio (NASDAQ:BOLD) was reported by Leerink Partners on April 22, 2024. The analyst firm set a price target for $25.00 expecting BOLD to rise to within 12 months (a possible 498.09% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Boundless Bio (NASDAQ:BOLD) was provided by Leerink Partners, and Boundless Bio initiated their outperform rating.

There is no last upgrade for Boundless Bio

There is no last downgrade for Boundless Bio.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Boundless Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Boundless Bio was filed on April 22, 2024 so you should expect the next rating to be made available sometime around April 22, 2025.

While ratings are subjective and will change, the latest Boundless Bio (BOLD) rating was a initiated with a price target of $0.00 to $25.00. The current price Boundless Bio (BOLD) is trading at is $4.18, which is within the analyst’s predicted range.